Skip to content
Agios Pharmaceuticals logo

Agios Pharmaceuticals

AGIO

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for rare diseases, with a primary focus on non-cancerous hematological disorders.

Market cap
$2.2B+1.1%
Revenue$66.0M+78.3%
Net income-$422.6M-162%
Free cash flow-$384.7M+4.7%
EPS (diluted)-$7.25-163%
Trailing twelve months · change vs. prior year

Earnings

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$26.4M
EPS estimate-$1.65

Financials

Q1 2026

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation & ratios

Valuation

See full
Market cap$2.2B+1.1%
Enterprise value$2.12B-0.1%
P/S33.3×-19.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Competitors

Profile

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for rare diseases, with a primary focus on non-cancerous hematological disorders. The company leverages its expertise in cellular metabolism to target enzyme deficiencies, aiming to establish a standard of care for hemolytic anemias and other metabolic conditions. Its value proposition centers on a first-in-class PK activator franchise and a robust clinical pipeline addressing significant unmet medical needs in rare disease communities.

Competitive position

Agios is a leader in the PK activator space with the first-in-class therapy mitapivat, maintaining full ownership of its lead assets in the U.S. while utilizing strategic partnerships for international commercialization.

GeographiesUnited States, European Union, Great Britain, Saudi Arabia, Gulf Council Countries
Customer segmentsRare disease patients, Healthcare providers, Government health programs, Commercial insurers
Business modelResearch and Development, Product Sales, Licensing and Royalties
SuppliersContract manufacturing organizations (CMOs), Third-party active pharmaceutical ingredient (API) suppliers, Clinical trial sites and investigators
CustomersSpecialty pharmacies, Wholesale drug distributors, Hospitals, Government and private health payors
Listed2013
Employees386.0
CEOBrian Goff
Websiteagios.com
FilingsSEC EDGAR

Questions, answered.

What is Agios Pharmaceuticals's market cap?
Agios Pharmaceuticals (AGIO) has a market capitalization of $2.2B and trades on NASDAQ.
What is Agios Pharmaceuticals's revenue and profitability?
Agios Pharmaceuticals generated $66.0M in trailing twelve-month revenue with a net loss of $422.6M, representing a net margin of -639.8%. Gross margin stands at 90.0%, with free cash flow of -$384.7M. These figures are based on the Q1 2026 filing.
Who are Agios Pharmaceuticals's competitors?
Agios Pharmaceuticals's key competitors include Incyte Corporation, Vertex Pharmaceuticals Incorporated, BioMarin Pharmaceutical, Inc., and others. These companies compete in similar markets and product categories.
Who does Agios Pharmaceuticals partner with?
Agios Pharmaceuticals's notable partners include Alnylam Pharmaceuticals, Inc., Servier Pharmaceuticals, LLC, Royalty Pharma, and others.
Where is Agios Pharmaceuticals headquartered?
Agios Pharmaceuticals is headquartered in United States of America and employs approximately 386 people. It has been publicly traded since 2013.